+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Molecular, Conventional), Infection Type (UTI, Pneumonia), Product (Consumables, Instruments), Type, Country with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Europe
  • Grand View Research
  • ID: 6056053
Description Jump to:
The Europe Hospital Acquired Infections Diagnostics Market was valued at USD 1.48 billion in 2024, and is projected to reach USD 1.61 billion by 2030, rising at a CAGR of 1.20%. In recent years, the prevalence of infections, particularly sepsis and surgical site infections, has driven a surge in demand for effective diagnostic solutions. In Europe, approximately 3.4 million sepsis cases occurred annually, leading to nearly 700,000 deaths each year, highlighting the urgent need for advanced diagnostic tools. The rising incidence of bloodstream infections (BSIs) compelled healthcare providers to implement robust diagnostic measures, presenting substantial market opportunities for companies specializing in hospital-acquired infection (HAI) diagnostics.

Technological advancements significantly contributed to market growth, with innovations in molecular diagnostics and rapid testing methods enhancing the accuracy and speed of HAI detection. These developments allowed for more timely identification, ultimately improving patient outcomes.

In addition, increasing healthcare expenditure across European countries facilitated the adoption of HAI diagnostics. Investments in healthcare infrastructure and proactive government initiatives aimed at infection control fostered a supportive environment for market expansion. Heightened patient awareness regarding HAIs further amplified the demand for effective diagnostic solutions, as informed patients and healthcare providers alike sought timely diagnostics, propelling market growth for innovative diagnostic products.

Europe Hospital Acquired Infections Diagnostics Market Report Highlights

  • Based on test type, the conventional tests dominated the market in 2024. Molecular tests, especially PCR-based methods, are projected to achieve the fastest CAGR of 1.5% during the forecast period, becoming essential for diagnosing hospital-acquired infections in Europe.
  • Based on infection type, the UTI segment led the Europe hospital acquired infections diagnostics industry in 2024, accounting for a revenue share of 21.6% in 2024.
  • In 2024, the consumables product segment captured the highest market share, driven by the need for accurate diagnosis, regulatory compliance, and high testing volumes in European hospitals.
  • Based on type, the urinalysis segment is expected to grow lucratively due to rising UTI rates in hospitals, particularly in urology units, driven by high catheterization and demand for effective diagnostics.
  • Key players operating in the market include BIOMÉRIEUX; Abbott; F. Hoffmann-La Roche Ltd; Siemens Healthineers AG; BD; HC Bioscience; QIAGEN; Thermo Fisher Scientific Inc.; Meridian Bioscience, Inc.; Hologic, Inc.
  • In January 2025, BioMerieux announced its intent to pursue acquisitions with EUR 3bn- EUR 4bn available, enhancing its core segments within the diagnostics market.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test Type
1.2.2. Infection Type
1.2.3. Product
1.2.4. Type
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Europe Hospital Acquired Infections Diagnostics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Europe Hospital Acquired Infections Diagnostics Market: Test Type Business Analysis
4.1. Test Type Market Share, 2024 & 2030
4.2. Test Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2018 to 2030 (USD Million)
4.4. Molecular
4.4.1. Molecular Market, 2018-2030 (USD Million)
4.5. Conventional
4.5.1. Conventional Market, 2018-2030 (USD Million)
Chapter 5. Europe Hospital Acquired Infections Diagnostics Market: Infection Type Business Analysis
5.1. Infection Type Market Share, 2024 & 2030
5.2. Infection Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Infection Type, 2018 to 2030 (USD Million)
5.4. UTI
5.4.1. UTI Market, 2018-2030 (USD Million)
5.5. Pneumonia
5.5.1. Pneumonia Market, 2018-2030 (USD Million)
5.6. Surgical Site Infection
5.6.1. Surgical Site Infection Market, 2018-2030 (USD Million)
5.7. Blood Stream Infections
5.7.1. Blood Stream Infections Market, 2018-2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Europe Hospital Acquired Infections Diagnostics Market: Product Business Analysis
6.1. Product Market Share, 2024 & 2030
6.2. Product Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
6.4. Consumables
6.4.1. Consumables Market, 2018-2030 (USD Million)
6.5. Instruments
6.5.1. Instruments Market, 2018-2030 (USD Million)
Chapter 7. Europe Hospital Acquired Infections Diagnostics Market: Type Business Analysis
7.1. Type Market Share, 2024 & 2030
7.2. Type Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
7.4. Blood Tests
7.4.1. Blood Tests Market, 2018-2030 (USD Million)
7.5. Urinalysis
7.5.1. Urinalysis Market, 2018-2030 (USD Million)
Chapter 8. Europe Hospital Acquired Infections Diagnostics Market: Regional Estimates & Trend Analysis
8.1. Country Market Share Analysis, 2024 & 2030
8.2. Country Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. UK
8.4.1. Key Country Dynamics
8.4.2. Regulatory Framework
8.4.3. Competitive Insights
8.4.4. UK Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.5. Germany
8.5.1. Key Country Dynamics
8.5.2. Regulatory Framework
8.5.3. Competitive Insights
8.5.4. Germany Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.6. France
8.6.1. Key Country Dynamics
8.6.2. Regulatory Framework
8.6.3. Competitive Insights
8.6.4. France Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.7. Italy
8.7.1. Key Country Dynamics
8.7.2. Regulatory Framework
8.7.3. Competitive Insights
8.7.4. Italy Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.8. Spain
8.8.1. Key Country Dynamics
8.8.2. Regulatory Framework
8.8.3. Competitive Insights
8.8.4. Spain Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.9. Norway
8.9.1. Key Country Dynamics
8.9.2. Regulatory Framework
8.9.3. Competitive Insights
8.9.4. Norway Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.10. Denmark
8.10.1. Key Country Dynamics
8.10.2. Regulatory Framework
8.10.3. Competitive Insights
8.10.4. Denmark Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.11. Sweden
8.11.1. Key Country Dynamics
8.11.2. Regulatory Framework
8.11.3. Competitive Insights
8.11.4. Sweden Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.12. Russia
8.12.1. Key Country Dynamics
8.12.2. Regulatory Framework
8.12.3. Competitive Insights
8.12.4. Russia Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.13. Netherlands
8.13.1. Key Country Dynamics
8.13.2. Regulatory Framework
8.13.3. Competitive Insights
8.13.4. Netherlands Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. BIOMÉRIEUX
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Abbott
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. F. Hoffmann-La Roche Ltd
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Siemens Healthineers AG
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. BD
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. HC Bioscience
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. QIAGEN
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Thermo Fisher Scientific Inc.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Meridian Bioscience, Inc.
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Hologic, Inc.
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Europe hospital acquired infections diagnostics market, by country, 2018-2030 (USD Million)
Table 4. Europe hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 5. Europe hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 6. Europe hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 7. Europe hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 8. UK hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 9. UK hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 10. UK hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 11. UK hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 12. Germany hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 13. Germany hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 14. Germany hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 15. Germany hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 16. France hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 17. France hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 18. France hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 19. France hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 20. Italy hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 21. Italy hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 22. Italy hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 23. Italy hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 24. Spain hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 25. Spain hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 26. Spain hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 27. Spain hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 28. Denmark hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 29. Denmark hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 30. Denmark hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 31. Denmark hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 32. Sweden hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 33. Sweden hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 34. Sweden hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 35. Sweden hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 36. Norway hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 37. Norway hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 38. Norway hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 39. Norway hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 40. Russia hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 41. Russia hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 42. Russia hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 43. Russia hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
Table 44. Netherlands hospital acquired infections diagnostics market, by test type, 2018-2030 (USD Million)
Table 45. Netherlands hospital acquired infections diagnostics market, by infection type, 2018-2030 (USD Million)
Table 46. Netherlands hospital acquired infections diagnostics market, by product, 2018-2030 (USD Million)
Table 47. Netherlands hospital acquired infections diagnostics market, by type, 2018-2030 (USD Million)
List of Figures
Figure 1 Europe hospital acquired infections diagnostics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Test type and infection type outlook (USD Million)
Figure 10 Product and type outlook (USD Million)
Figure 11 Competitive landscape
Figure 12 Europe hospital acquired infections diagnostics market dynamics
Figure 13 Europe hospital acquired infections diagnostics market: Porter’s five forces analysis
Figure 14 Europe hospital acquired infections diagnostics market: PESTLE analysis
Figure 15 Europe hospital acquired infections diagnostics market: Test type segment dashboard
Figure 16 Europe hospital acquired infections diagnostics market: Test type market share analysis, 2024 & 2030
Figure 17 Molecular market, 2018-2030 (USD Million)
Figure 18 Conventional market, 2018-2030 (USD Million)
Figure 19 Europe hospital acquired infections diagnostics market: Infection type segment dashboard
Figure 20 Europe hospital acquired infections diagnostics market: Infection type market share analysis, 2024 & 2030
Figure 21 UTI market, 2018-2030 (USD Million)
Figure 22 Pneumonia market, 2018-2030 (USD Million)
Figure 23 Surgical site infection market, 2018-2030 (USD Million)
Figure 24 Blood stream infections market, 2018-2030 (USD Million)
Figure 25 Others market, 2018-2030 (USD Million)
Figure 26 Europe hospital acquired infections diagnostics market: Product segment dashboard
Figure 27 Europe hospital acquired infections diagnostics market: Product market share analysis, 2024 & 2030
Figure 28 Consumables market, 2018-2030 (USD Million)
Figure 29 Instruments market, 2018-2030 (USD Million)
Figure 30 Europe hospital acquired infections diagnostics market: Type segment dashboard
Figure 31 Europe hospital acquired infections diagnostics market: Type market share analysis, 2024 & 2030
Figure 32 Blood tests market, 2018-2030 (USD Million)
Figure 33 Urinalysis market, 2018-2030 (USD Million)
Figure 34 Europe hospital acquired infections diagnostics market revenue, by region
Figure 35 Regional marketplace: Key takeaways
Figure 36 Regional marketplace: Key takeaways
Figure 37 UK country dynamics
Figure 38 UK hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 39 Germany country dynamics
Figure 40 Germany hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 41 France country dynamics
Figure 42 France hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 43 Italy country dynamics
Figure 44 Italy hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 45 Spain country dynamics
Figure 46 Spain hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 47 Norway country dynamics
Figure 48 Norway hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 49 Sweden country dynamics
Figure 50 Sweden hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 51 Denmark country dynamics
Figure 52 Denmark hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 53 Russia country dynamics
Figure 54 Russia hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 55 Netherlands country dynamics
Figure 56 Netherlands hospital acquired infections diagnostics market, 2018-2030 (USD Million)
Figure 57 Company categorization
Figure 58 Company market position analysis
Figure 59 Strategic framework

Companies Mentioned

The major companies profiled in this Europe Hospital Acquired Infections Diagnostics market report include:
  • BIOMÉRIEUX
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • BD
  • HC Bioscience
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Meridian Bioscience, Inc.
  • Hologic, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.61 Billion
Compound Annual Growth Rate1.2%
Regions CoveredEurope
No. of Companies Mentioned10

Related Topics

Related Reports

Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test (Molecular, Conventional), Infection (UTI, Pneumonia), Product, Type, and Region with Growth Forecasts, 2025-2030 - Product Image

Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test (Molecular, Conventional), Infection (UTI, Pneumonia), Product, Type, and Region with Growth Forecasts, 2025-2030

  • Report
  • 70 Pages
  • Global
From
Hospital Acquired Infection Control Market by Type, Indication, End-user - Global Forecast 2025-2030 - Product Image

Hospital Acquired Infection Control Market by Type, Indication, End-user - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Hospital Acquired Infection Control Market Size, Share and Trends Analysis Report by Type (Equipment, Services, Consumables), End-use (Hospitals & ICUs, Ambulatory Surgical and Diagnostic Centers), and Region 2024-2030 - Product Image

Hospital Acquired Infection Control Market Size, Share and Trends Analysis Report by Type (Equipment, Services, Consumables), End-use (Hospitals & ICUs, Ambulatory Surgical and Diagnostic Centers), and Region 2024-2030

  • Report
  • 120 Pages
  • Global
From
Healthcare-associated Infectious Disease Diagnostics Market by Product & Service, Disease Type, End-user - Global Forecast 2025-2030 - Product Image

Healthcare-associated Infectious Disease Diagnostics Market by Product & Service, Disease Type, End-user - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Hospital Acquired Infections Testing Kits Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Hospital Acquired Infections Testing Kits Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 153 Pages
  • Global
From

About the Hospital Acquired Infection Diagnostics Market

The Hospital Acquired Infection Diagnostics market is a subset of the Infectious Disease Testing market. It focuses on the diagnosis of infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). Diagnostics for these infections are typically conducted using molecular testing, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests are used to detect the presence of the pathogen, as well as to identify the strain and its resistance to antibiotics. The Hospital Acquired Infection Diagnostics market is driven by the increasing prevalence of hospital-acquired infections, as well as the need for rapid and accurate diagnosis. This is especially important in the case of antibiotic-resistant infections, as timely diagnosis and treatment can help reduce the spread of the infection. Some companies in the Hospital Acquired Infection Diagnostics market include Cepheid, Hologic, Becton Dickinson, Roche, and Abbott. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.